Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Fish and Richardson
Healthtrust
Moodys
Deloitte
Colorcon
Covington
Chubb
Novartis
Cipla

Generated: October 17, 2017

DrugPatentWatch Database Preview

Ospemifene - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ospemifene and what is the scope of ospemifene patent protection?

Ospemifene
is the generic ingredient in one branded drug marketed by Duchesnay and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ospemifene has eighty-nine patent family members in thirty-one countries and twelve supplementary protection certificates in ten countries.

There are five drug master file entries for ospemifene. One supplier is listed for this compound.

Summary for Generic Name: ospemifene

US Patents:7
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: see list5
Suppliers / Packagers: see list1
Bulk Api Vendors: see list27
Clinical Trials: see list9
Patent Applications: see list58
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:ospemifene at DailyMed

Pharmacology for Ingredient: ospemifene

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Duchesnay
OSPHENA
ospemifene
TABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Duchesnay
OSPHENA
ospemifene
TABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Duchesnay
OSPHENA
ospemifene
TABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Duchesnay
OSPHENA
ospemifene
TABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Duchesnay
OSPHENA
ospemifene
TABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Duchesnay
OSPHENA
ospemifene
TABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Duchesnay
OSPHENA
ospemifene
TABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► SubscribeY ► Subscribe
Duchesnay
OSPHENA
ospemifene
TABLET;ORAL203505-001Feb 26, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: ospemifene

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,984,665Methods for the inhibition of atrophy or for treatment or prevention of atrophy-related symptoms in women► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ospemifene

Country Document Number Estimated Expiration
European Patent Office1713458► Subscribe
Germany60112301► Subscribe
Russian Federation2011112362► Subscribe
Australia5844901► Subscribe
Japan2014141533► Subscribe
Slovenia1305014► Subscribe
Portugal1305014► Subscribe
Norway20063960► Subscribe
Spain2364970► Subscribe
Norway20151603► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: OSPEMIFENE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
736Luxembourg► SubscribePRODUCT NAME: OSPEMIFENE DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; FIRST REGISTRATION: 20150115
00742Netherlands► SubscribePRODUCT NAME: OSPEMIFEEN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/14/978 20150115
0150029 00165Estonia► SubscribePRODUCT NAME: OSPEMIFEEN;REG NO/DATE: EU/1/14/978 19.01.2015
2015 00031Denmark► SubscribePRODUCT NAME: OSPEMIFENE OR A GEOMETRIC ISOMER THEREOF, A STEREOISOMER THEREOF, A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AN ESTER THEREOF OR A METABOLITE THEREOF; REG. NO/DATE: EU/1/14/978/001-002 20150115
6 5010-2015Slovakia► SubscribePRODUCT NAME: OSPEMIFEN; REGISTRATION NO/DATE: EU/1/14/978 20150119
2015 00031Denmark► SubscribePRODUCT NAME: OSPEMIFENE; REG. NO/DATE: EU/1/14/978/001-002 20150115
90030-1Sweden► SubscribePRODUCT NAME: OSPEMIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/14/978/001 20150119
2015023,C1713458Lithuania► SubscribePRODUCT NAME: OSPEMIFENAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/978/001, 2015 01 15 EU/1/14/978/002 20150115
C0041France► SubscribePRODUCT NAME: OSPEMIFENE DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/978 20150115
15/031Ireland► SubscribePRODUCT NAME: OSPEMIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTRATION NO/DATE: EU/1/14/978/001-002 20150115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
US Army
Dow
Julphar
Citi
Cantor Fitzgerald
Deloitte
Accenture
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot